Evaluation of cleaved caspase-3 and Ki-67 index on diagnostic biopsy in response to neoadjuvant chemotherapy in the context of post-treatment tumour ypT stage, ypN stage, grade, and molecular subtype.

Ki-67 breast cancer cleaved caspase-3 diagnostic biopsy of breast cancer neoadjuvant chemotherapy prognostic biomarkers

Journal

Przeglad menopauzalny = Menopause review
ISSN: 1643-8876
Titre abrégé: Prz Menopauzalny
Pays: Poland
ID NLM: 101263235

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 12 12 2023
accepted: 01 02 2024
medline: 1 5 2024
pubmed: 1 5 2024
entrez: 1 5 2024
Statut: ppublish

Résumé

Breast carcinoma is a heterogeneous disease, characterised by diverse clinical behaviour. The aim of this study was to assess how cleaved caspase-3 and Ki-67 index, evaluated on diagnostic biopsy, are related to response to neoadjuvant chemotherapy in the context of molecular subtype, post-treatment tumour, N category, and grade. A retrospective analysis was carried out among 110 breast cancer patients. Ki-67 levels and caspase-3 expression on diagnostic biopsy were explored regarding their relation to tumour grade and molecular subtype, ypT, ypN categories, and T and N categories according to Sataloff tumour response evaluation. A statistically significant relationship was found between Ki-67 levels and tumour grade K-W = 24.2932, No significant difference was found between Ki-67 expression in patients with pathological complete response, compared to those with partial and no response, a statistically significant difference in cases with different molecular subtype, histology grade, and tumour stage after neoadjuvant therapy. Cleaved caspase-3-positive breast cancer cases are often better responders to neoadjuvant therapy, but with no significant correlation to molecular subtype, high-grade categories, or tumour stage. The caspase-3 and Ki-67 index on diagnostic biopsy are related to post-neoadjuvant treatment prognostic factors (ypT stage, grade), proving them useful for prediction of treatment response to neoadjuvant therapy and further patient management.

Identifiants

pubmed: 38690065
doi: 10.5114/pm.2024.136962
pii: 52709
pmc: PMC11056723
doi:

Types de publication

Journal Article

Langues

eng

Pagination

31-40

Informations de copyright

Copyright © 2023 Termedia.

Déclaration de conflit d'intérêts

The authors report no conflict of interest.

Auteurs

Vasil Nanev (V)

Medical University of Pleven, Pleven, Bulgaria.

Hristo Milev (H)

MHAT "Medika", Ruse, Bulgaria.

Desislava Dimitrova (D)

MHAT "Medika", Ruse, Bulgaria.

Silvia Naneva (S)

UMHAT "D-r Georgi Stranski", Pleven, Bulgaria.

Strahil Asenov Strashilov (SA)

Medical University of Pleven, Pleven, Bulgaria.

Angel Yordanov (A)

Medical University of Pleven, Pleven, Bulgaria.

Miroslava Mihailova (M)

UMHAT "D-r Georgi Stranski", Pleven, Bulgaria.

Simoneta Ivanova (S)

UMHAT "D-r Georgi Stranski", Pleven, Bulgaria.

Milena Karcheva (M)

Medical University of Pleven, Pleven, Bulgaria.

Ivan Ivanov (I)

Medical University of Pleven, Pleven, Bulgaria.

Classifications MeSH